Monitoring and Management of HbA1c

A patient with type 2 diabetes and an HbA1c of 52 mmol/mol, despite regular use of metformin for 3 months (correct)

A patient with type 2 diabetes and an HbA1c of 55 mmol/mol, despite regular use of metformin for 6 months

A patient with type 2 diabetes and an HbA1c of 48 mmol/mol, despite regular use of metformin for 4 months

A patient with type 2 diabetes and an HbA1c of 50 mmol/mol, despite regular use of metformin for 2 months

Diabetic renal disease

Known CV disease

Māori or Pacific ethnicity

Five-year CV risk < 15% (correct)

Because these agents are more effective in these groups

To reduce barriers in high-risk populations (correct)

Because of financial constraints

To exclude certain patient populations

<p>Patients who meet the Special Authority criteria for one agent and would benefit from dual SGLT2i/GLP1RA therapy</p> Signup and view all the answers

<p>Financial constraints</p> Signup and view all the answers

<p>Additional reductions in glucose levels and weight</p> Signup and view all the answers

<p>A patient with type 2 diabetes and an HbA1c of 50 mmol/mol, despite regular use of metformin for 3 months</p> Signup and view all the answers

<p>To ensure only the most severe cases receive funded SGLT2i and GLP1RA therapy</p> Signup and view all the answers